Showing results (271-280 of 427) with videos related to
Sort By:
Pageof 43
Acta Oncologica (Stockholm, Sweden)|August 31, 2021
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocolsSerena Rosati, Carmelo Gurnari, Massimo Breccia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patientsIlaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti, et al.European Journal of Haematology|May 23, 2020
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group"Maria Gabriella Mazzucconi, Ermina Baldacci, Roberto Latagliata, et al.Leukemia|May 28, 2025
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyureaFrancesca Palandri, Massimo Breccia, Elena M Elli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional DatabaseMaria Teresa Voso, Susanna Fenu, Roberto Latagliata, et al.Hematological Oncology|July 21, 2012
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemiaRoberto Latagliata, Massimo Breccia, Carmen Fava, et al.Leukemia|December 22, 2018
Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemiaFabio Efficace, Massimo Breccia, Giuseppe Avvisati, et al.Haematologica|January 16, 2009
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-upFrancesca Palandri, Fausto Castagnetti, Giuliana Alimena, et al.Annals of Hematology|November 28, 2016
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPNMassimo Breccia, Alessandro Andriani, Marco Montanaro, et al.Haematologica|July 18, 2012
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitorsAntonella Russo Rossi, Massimo Breccia, Elisabetta Abruzzese, et al.Pageof 43